一磷酸鞘氨醇在哮喘炎症细胞水平的研究进展  

Research progress of sphingosine 1-phosphate in inflammatory cell levels ofasthma

作　　者：刘函晔 陈正爱[1] 刘卫东 崔弘(指导) LIU Han-Ye;CHEN Zheng-Ai;LIU Wei-Dong;CUI Hong(School of Basic Medicine of Yianbian University,Yanji 133002,China)

机构地区：[1]延边大学基础医学院,延吉133002

出　　处：《中国免疫学杂志》2020年第14期1771-1774,共4页Chinese Journal of Immunology

基　　金：国家自然科学基金(No.81460001);吉林省教育厅“十三五”科学技术项目(No.JJKH20180908KJ);吉林省科技发展计划(No.20180101131JC)项目资助。

摘　　要：哮喘是由多种炎症细胞及细胞组分介导的慢性气道炎症性疾病,该炎症常伴随气道反应性增高,支气管上皮结构功能异常,严重时引发气道重塑,加重哮喘发生。目前的治疗包括吸入长效β-肾上腺素能受体激动剂和抗炎糖皮质激素。一磷酸鞘氨醇(S1P)是一种具有生物活性的鞘脂代谢物,在哮喘等过敏反应中起重要作用。本综述旨在归纳整理S1P及其受体在哮喘中相关作用的研究进展。Asthma is a chronic airway inflammatory disease mediated by a variety of inflammatory cells and cellular components.This inflammation is often accompanied by increased airway responsiveness,abnormal bronchial epithelial structure,severe cases result in airway remodeling,aggravate the occurrence of asthma.Current treatments include inhaled long-acting beta-adrenergic agonists and corticosteroids.Sphingosine 1-phosphate(S1P)is a biologically active sphingolipid metabolite which plays an important role in allergic reactions such as asthma.This review aims to summarize the research progress of S1P and its receptors in the role of asthma.

关 键 词：一磷酸鞘氨醇 受体 哮喘 细胞代谢 

分 类 号：R363[医药卫生—病理学] R562[医药卫生—基础医学]